The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy ...
The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...
Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as ...
News-Medical.Net on MSN
Newly discovered survival pathway explains stubborn EGFR-driven lung cancers
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth ...
Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results